Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.16
-0.0200-1.69%
Post-market: 1.190.0300+2.59%19:37 EDT
Volume:3.79M
Turnover:4.51M
Market Cap:252.03M
PE:-0.88
High:1.28
Open:1.19
Low:1.15
Close:1.18
Loading ...

Allogene Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Yesterday

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
30 Apr

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%

Simply Wall St.
·
25 Apr

Allogene Therapeutics to present updated ALLO-316 results at ASCO meeting

TIPRANKS
·
23 Apr

William Blair Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
21 Apr

William Blair Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
10 Apr

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Zacks
·
08 Apr

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases

MT Newswires Live
·
07 Apr

BRIEF-Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329

Reuters
·
07 Apr

Allogene Therapeutics granted three Fast Track Designations for ALLO-329

TIPRANKS
·
07 Apr

Allogene Therapeutics Shares up 2.8% Premarket After Co Granted Three FDA Fast Track Designations for Allo-329

THOMSON REUTERS
·
07 Apr

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) for Allo-329, a Next-Generation Dual-Targeted Cd19/Cd70 Allogeneic Car T, for the Treatment of Lupus, Myositis and Scleroderma

THOMSON REUTERS
·
07 Apr

Allogene Therapeutics Inc: Expects to Initiate Phase 1 Resolution Basket Trial in Mid-2025

THOMSON REUTERS
·
07 Apr

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

GlobeNewswire
·
07 Apr

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

GlobeNewswire
·
28 Mar

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Mar

Allogene Therapeutics Price Target Maintained With a $10.00/Share by RBC Capital

Dow Jones
·
14 Mar

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Zacks
·
14 Mar

RBC Capital Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Mar

TD Cowen Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Mar